hydroxyflutamide has been researched along with finasteride in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Labrie, F; Li, X; Singh, SM | 1 |
| Côté, J; Labrie, F; Laplante, S; Li, X; Singh, SM; Veilleux, R | 1 |
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Gorczynska, E; Handelsman, DJ | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Muzi, P; Vicentini, C | 1 |
| Danielpour, D; Lucia, MS; Roberts, AB; Sporn, MB; Stewart, LV | 1 |
| Chung, K; Dalton, JT; Gao, W; Kearbey, JD; Miller, DD; Nair, VA; Parlow, AF | 1 |
7 other study(ies) available for hydroxyflutamide and finasteride
| Article | Year |
|---|---|
Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
Topics: Androgen Receptor Antagonists; Androstanes; Animals; Aza Compounds; Cell Division; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Oxidoreductases; Structure-Activity Relationship; Testosterone; Tumor Cells, Cultured | 1995 |
Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstenes; Animals; Cell Division; Humans; Mice; Tumor Cells, Cultured | 1995 |
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
Androgens rapidly increase the cytosolic calcium concentration in Sertoli cells.
Topics: Androgen Antagonists; Androgens; Animals; Calcium; Cells, Cultured; Cyclic AMP; Cytosol; Dihydrotestosterone; Drug Synergism; Finasteride; Flutamide; Follicle Stimulating Hormone; Kinetics; Male; Progesterone; Rats; Rats, Wistar; Sertoli Cells; Spermatogenesis; Testosterone; Time Factors | 1995 |
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Finasteride; Flutamide; Humans; Linear Models; Male; Prostatic Neoplasms; Testosterone; Tumor Cells, Cultured | 1995 |
The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells.
Topics: Androgen Antagonists; Androgens; Animals; Antibodies; Cell Division; Cell Line; Dihydrotestosterone; Down-Regulation; Finasteride; Flutamide; Male; Prostate; Rats; Testosterone; Transforming Growth Factor beta | 1998 |
Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens; Animals; Enzyme Inhibitors; Finasteride; Flutamide; Male; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testis | 2004 |